Technology | December 22, 2014

AliveCor Launches Third Generation Heart Monitor Smartphone App System

New compact medical grade mobile ECG device is 50-percent thinner, 40-percent lighter

AliveCor Heart Monitor, third generation, ECG, atrial fibrillation, AF

December 22, 2014 — AliveCor Inc. announced the launch of its third-generation AliveCor Heart Monitor. Now users have the ability to identify and manage heart conditions with a U.S. Food and Drug Administration (FDA)-cleared electrocardiogram (ECG) monitor, anywhere and at anytime. The third-generation device is now 50-percent thinner and 40-percent lighter and was designed from first-hand customer feedback and in collaboration with global design firm IDEO.

Atrial fibrillation (AF) continues to be the most common heart rhythm disturbance, affecting more than 140 million people worldwide. AliveCor is focused on helping those with diagnosed and undiagnosed heart conditions, by providing patients and caregivers a tool to detect and manage heart conditions.

Users of the AliveCor Heart Monitor are recording 130,000 ECGs per month and actively tracking over 10,000 symptoms, medications and activities that may be affecting their health. In the two months since the AF Detector algorithm was launched, AliveCor has detected more than 20,000 incidents of AF in more than 30 percent of users recording ECGs.

Detecting AF is the first step to initiating a treatment plan to reduce stroke risk, as people with AF are five times more likely to suffer a stroke than those without the condition. Additionally, users continue to engage with the product over time: 70 percent are regularly using the device after six months.

“I used to get frustrated when I would experience what I thought was an AF episode but couldn’t get to the doctor’s office fast enough to confirm my instincts,” said Terry Reilly, AliveCor patient since 2012. “With the AliveCor Heart Monitor, I am relieved to have an easy-to-use tool at my fingertips that can instantly detect my AF episodes when they happen.”

“The AliveCor Heart Monitor leads to results that I can use to manage my patients remotely, a trend that is here to stay," said Jeffrey Olgin, M.D., chief, division of cardiology co-director, Heart and Vascular Center at the University of California San Francisco. “Seeing my patients’ ECG results in real-time is the next best thing to having them in my office when the event takes place.” 

“Big data and personalized medicine are revolutionizing the delivery of care and have the potential to disrupt the way we think about healthcare. We are excited to be on the forefront of helping patients manage their cardiac health,” said Euan Thomson, president and chief executive officer at AliveCor. “The newest generation of the Heart Monitor confirms AliveCor’s ongoing commitment to help stop the unnecessary loss of life and healthcare costs driven by undiagnosed and under-managed heart arrhythmias that lead to potentially life-threatening conditions like strokes.”

For more information:

Related Content

Boston Scientific's Apama multi-electrode ablation balloon to treat atrial fibrillation.

Boston Scientific's Apama multi-electrode ablation balloon to treat atrial fibrillation. The technology allows different energies to be used for each electrode to prevent damage to the esophagus or other underlying critical structures. 

Feature | Atrial Fibrillation | January 15, 2018 | Dave Fornell
The development of atrial fibrillation (AFib or AF) ablation technologies over the past 20 years has been a constant
Heart Rhythm Society Partners With WebMD Education to Increase Atrial Fibrillation Awareness
News | Atrial Fibrillation | January 02, 2018
The Heart Rhythm Society (HRS), in partnership with WebMD Education, announced in December the launch of a free, online...
The Boston Scientific Rhythmia Mapping System produces higher-density voltage maps without increasing overall procedure time.

The Boston Scientific Rhythmia Mapping System produces higher-density voltage maps without increasing overall procedure time. It was the first of a new generation of high-density mapping systems to be introduced.

Feature | Atrial Fibrillation | December 18, 2017 | Kenneth Stein, M.D. FACC FHRS
When I began practicing as an electrophysiologist in 1994, the dream of successfully using cardiac catheter ablation
Acutus dipole density EP mapping for ablation procedures.

The FDA recently cleared high-speed Acutus Medical's AcQMap High Resolution image and mapping system and the AcQMap 3-D Imaging and Mapping Catheter.  detects and displays both standard voltage-based and higher resolution dipole density (charge-source) maps. The system combines ultrasound anatomy construction with an ability to map the electrical-conduction of each heartbeat to identify complex arrhythmias across the entire atrial chamber. Following each ablation treatment, the heart can be re-mapped in seconds to continually visualize any changes from the prior mapping.



Feature | Atrial Fibrillation | November 07, 2017
November 7, 2017 — Here is an aggregated list of articles detailing the latest clinical data and new device technolog
The Watchman LAA occluder PREVAIL Trial 5-year results were presented at the 2017 TCT meeting.
Feature | Atrial Fibrillation | November 02, 2017
November 2, 2017 – Five-year results from the PREVAIL Trial comparing left atrial appendage closure (LAAC) with the B
UNC School of Medicine Receives $1.7 Million for Atrial Fibrillation Program Streamlining Patient Care
News | Atrial Fibrillation | October 23, 2017
October 23, 2017 — University of North Carolina (UNC) School of Medicine cardiologist Anil Gehi, M.D., will use a $1.
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation | September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation | September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
Overlay Init